Shares of Novo Nordisk (NVO) surged more than 7% on Tuesday, with trading volume spiking nearly 300% above its recent average. The catalyst was the U.S. Food and Drug Administration (FDA) approval of the company’s once-daily oral version of its blockbuster weight-loss drug, Wegovy.
This long-anticipated pill is seen as a potential game-changer. But can it help the Danish pharmaceutical giant mount a comeback after a brutal year that has seen its stock plummet roughly 44%?
The approved oral semaglutide is indicated for chronic weight management in adults. Clinical trials showed an average weight loss of 16.6%, efficacy on par with the injectable form of Wegovy. Novo Nordisk CEO Mike Doustdar emphasized that the pill offers a new, convenient option for patients who are averse to injections. The company plans to launch the medication in the United States in early January.
The approval grants Novo Nordisk a valuable first-mover advantage in the oral GLP-1 segment. Morgan Stanley estimates the global obesity drug market could approach a staggering $150 billion by 2035. The pill format is expected to significantly broaden the market by attracting patients with poor adherence to injectable therapies.
Despite today’s rally, 2025 has been punishing for Novo Nordisk shareholders. The stock’s 44% drop dramatically underperforms the broader healthcare sector. The pressure stems from multiple headwinds: compounded versions of its GLP-1 drugs (like Ozempic) eroding sales, a subsequent reduction in full-year growth guidance, and a recent CEO transition from Lars Fruergaard Jørgensen to Mike Doustdar. These factors combined into a “perfect storm” for the stock.
The steep decline has left Novo Nordisk trading near four-year lows, with a price-to-earnings (P/E) ratio of approximately 14—well below its historical average. Analysts suggest this beaten-down valuation may have already priced in the recent bad news. They see several potential catalysts for 2026, including the commercial launch of the oral Wegovy, ongoing legal efforts against compounding pharmacies, and the new management team executing its strategy. Any positive development could trigger a significant rebound from current levels.
The focus now shifts to the initial real-world demand for oral Wegovy upon its January launch. Early sales data, likely disclosed in the company’s early 2026 earnings report, will be a key test. Furthermore, the competitive landscape remains in flux, with progress from rivals like Eli Lilly (LLY) in developing their own oral weight-loss drugs poised to influence Novo Nordisk’s market position and valuation.
The arrival of the oral pill undoubtedly opens a new growth chapter for Novo Nordisk. However, whether Tuesday’s surge marks a definitive bottom for the stock, or just a respite in a challenging period, will depend on the drug’s commercial execution and the company’s ability to navigate ongoing competitive and operational pressures. The market awaits further proof.
